Full Press Release Details
Blue Water Vaccines Announces Institutional
Research Coverage by Two Notable Healthcare-Focused Wall Street Banks, Receives "Buy" Rating From Both
CINCINNATI, OH, December 12, 2022 -- Blue
Water Vaccines Inc. ("BWV" or "Blue Water Vaccines" or the "Company"), a biopharmaceutical company
developing transformational vaccines to address significant global health challenges, today announced its first analyst coverage
since going public in February 2022 with the initial recommendations as "buy" from both Maxim Group LLC ("Maxim")
and H.C. Wainwright & Co. ("H.C. Wainwright") at price targets of $4 and $7, respectively.
Copies of the full analyst report from Maxim and H.C. Wainwright, respectively,
can be obtained upon request directly from Maxim and H.C. Wainwright.
"We are thrilled to receive these
recommendations from such esteemed analysts and truly believe that both reports echo our internal beliefs about our groundbreaking
technology," said Joseph Hernandez, Chairman and Chief Executive Officer of Blue Water Vaccines. "While we feel that we
are undervalued in the current market, we believe these reports highlight our transformative vaccine programs to current and
potential investors and will hopefully show the true value in our mission as we advance our programs towards clinical
The research analysts primarily responsible for the preparation of
the Maxim and the H.C. Wainwright research reports have received compensation based upon various factors, including the respective firm's
total revenues, a portion of which is generated by investment banking activities. Maxim makes a market in Blue Water Vaccines. Each
of Maxim and HC Wainwright have received compensation for non-investment banking securities-related services from Blue Water Vaccines
in the past 12 months and may provide investment banking services in the future. HC Wainwright has previously received compensation for
investment banking services in the last 12 months but does currently not make a market in Blue Water Vaccines.
Although BWV has paid the above compensation to the analysts, BWV is
not responsible for the content, accuracy or timelines contained in an analyst's report and the fee was not dependent on the opinion
All reports on BWV prepared by analysts represent the views of such
analysts and are not necessarily those of BWV. BWV is not responsible for the content, accuracy or timelines provided by analysts. BWV
does not expressly or by implication warrant or assume any legal liability or responsibility for the accuracy, completeness, or usefulness
of any information, assumption, data, forecast, price target, estimate or projection contained in the reports or industry notes provided
by analysts, and the dissemination of such reports or industry notes does not necessarily constitute or imply BWV's endorsement
About Blue Water Vaccines
Blue Water Vaccines Inc. is a biopharmaceutical company focused on
developing transformational vaccines to address significant health challenges globally. Headquartered in Cincinnati, OH, the company holds
the rights to proprietary technology developed at the University of Oxford, Cincinnati Children's Hospital Medical Center, St. Jude
Children's Hospital, and The University of Texas Health San Antonio. The Company is developing a universal flu vaccine that will
provide protection from all virulent strains in addition to licensing a novel norovirus (NoV) S&P nanoparticle versatile virus-like
particle (VLP) vaccine platform from Cincinnati Children's to develop vaccines for multiple infectious diseases, including norovirus/rotavirus
and malaria, among others. Additionally, Blue Water Vaccines is developing a Streptococcus pneumoniae (pneumococcus) vaccine
candidate, designed to specifically prevent the highly infectious middle ear infections, known as Acute Otitis Media (AOM), in children,
and prevention of pneumonia in older people at risk for contracting pneumococcal pneumonia, a significant unmet medical need. The advantage
of this technology includes a serotype independent mucosal immunity that prevents colonization in the upper respiratory tract as well
as systemic immunity that can confer serotype independent against invasive pneumococcal disease The Company is also developing a Chlamydia
vaccine candidate with UT Health San Antonio to prevent infection and reduce the need for antibiotic treatment associated with contracting
Chlamydia disease. For more information, visit www.bluewatervaccines.com.
Forward-Looking Statements
Certain statements in this press release are forward-looking within
the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking
words such as "anticipate," "believe," "forecast," "estimate," "expect," and
"intend," among others. These forward-looking statements are based on BWV's current expectations and actual results
could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such
forward-looking statements. These factors include, but are not limited to, risks related to the development of BWV's vaccine candidates;
the failure to obtain FDA clearances or approvals and noncompliance with FDA regulations; delays and uncertainties caused by the global
COVID-19 pandemic; risks related to the timing and progress of clinical development of our product candidates; our need for additional
financing; uncertainties of patent protection and litigation; uncertainties of government or third party payor reimbursement; limited
research and development efforts and dependence upon third parties; and substantial competition. As with any vaccine under development,
there are significant risks in the development, regulatory approval and commercialization of new products. BWV does not undertake an obligation
to update or revise any forward-looking statement. Investors should read the risk factors set forth in BWV's Registration Statement
on Form S-1, filed with the Securities and Exchange Commission (the "SEC") on August 29, 2022 and periodic reports filed with
the SEC on or after the date thereof. All of BWV's forward-looking statements are expressly qualified by all such risk factors and
other cautionary statements. The information set forth herein speaks only as of the date thereof.
Media Contact Information:
Blue Water Media Relations
Telephone: (646) 942-5591
Investor Contact Information:
Blue Water Investor Relations